-
FDA approves Lilly Taltz (ixekizumab) treatment for active orthodlamitis
Time of Update: 2021-02-24
In the ixekizumab group of COAST-V and COAST-W trials, 48% and 25% of patients reached the main endpoint ASASAS40, respectively, while the placebo group achieved 18% and 13%, respectively.
-
Oncodesign selects RIPK2 inhibitors to treat autoimmune and inflammation
Time of Update: 2021-02-24
, ONCODESIGN, a group specializing in precision medicine biopharmaceuticals, announced the selection of ODS-101 as a candidate for autoimmune and inflammatory disease adaptation.
Today, Oncodesign has chosen ODS-101 as a state-of-the-art oral RIPK2 inhibitor to drive industrial development research that will rapidly reach its expected industrial status by 2021.
-
Johnson and Johnson submitted an application for an Ebola vaccine to the EMA
Time of Update: 2021-02-24
Johnson and Johnson announced that it would submit its Ebola vaccine research program to the European Medicines Agency (EMA) for a listing permit.
-
Lilly announces the survival benefits of the new drug Verzenio
Time of Update: 2021-02-24
The drug is the first and only CDK4 and 6 inhibitors used in combination with fluovirus groups, and based on phase III MONARCH 2 studies, there is a significant statistical improvement in total survival rates in patients/post-menoanth and post-menoanthetic women who progress after endocrine therapy for cancer.
-
GSK submits a application for a new drug for daprodustat to MHLW Japan
Time of Update: 2021-02-24
recently, GlaxoSmithKline (gsk) submitted a new drug application (nda) to japan's Ministry of Health, Labour and Welfare (mhlw) for approval of oral hypooxygenated factor proline hydroxygen inhibitor (hif-phi) daprodustat to treat renal anemia caused by chronic kidney disease (ckd).
-
Turalio, a new drug used to treat tendon cytoblastoma, has been approved by the FDA for the first time
Time of Update: 2021-02-24
the U.S. Food and Drug Administration (FDA) approved Dayichi Sankyo's Pexidartinib capsule for the treatment of adult patients with tendon cytomoma (TGCT) symptoms, who are associated with severe morbidity or functional limitations and have not improved through surgery.
-
Ardelyx's Phase 3 trial to treat high phosphorusemia has reached its end
Time of Update: 2021-02-24
Once approved, Tenapanor could be the basic therapy for patients on CKD dialysis with elevated blood phosphorus concentrations, Ardelyx said.
Although these patients were treated with stable phosphate adhesives, blood phosphorus concentrations were ≥5.5 mg/dL at screening and ≤10.0 mg/dL.
-
GSK's Dovato reached the end of the study
Time of Update: 2021-02-24
earlier this year, Dovato monoliths were licensed in the United States to treat hiv-1 infections in adults with no history of antiretroviral therapy and no known resistance to dolutegravir or lamifding.
-
Bronger Ingham gave up BI1467335 for NASH adaptation
Time of Update: 2021-02-24
On December 18, local time, Bollinger Ingham and partner Pharmaxis announced that their SSAO/VAP-1 inhibitor BI 1467335 had not directly failed in the latest clinical study, but that the drug had been linked to other drugs and that the two sides had decided to abandon research and development of the drug for the treatment of fatty liver disease.
-
AstraZenecon Calquence first-line treatment CLL III clinical success
Time of Update: 2021-02-24
ELEVATE-TN (ACE-CL-007) is a randomized, multi-center, open-label Phase III study conducted in patients with previously un treated (primary treatment) CLL to assess the efficacy and safety of Calquence monotherapy, Calquence-obinutuzumab combination therapy and benzodiazepine nitrogen mustard-outuzumab combination therapy.
-
Researchers have uncovered experimental compounds to block treatment targets for blood cancer
Time of Update: 2021-02-24
“ We found a protein called Tyro3 that was highly increased to a non-Hodgkin's lymphoma subtype, called primary fluid lymphoma," said Dr. Blossom Damania, an associate researcher at the UNC Lineberger School of Medicine, a distinguished professor of microbiology and immunology at Cary C.
-
FDA approves new add-ons for the treatment of Parkinson's disease in adults
Time of Update: 2021-02-24
“ Parkinson's disease is a debilitating disease that severely affects a patient's life," said Eric Bastings, acting director of neurology products at the FDA's Center for Drug Evaluation and Research.
-
Green leaf pharmaceutical high-dose Liss' permeable skin patch has been approved for sale in Germany
Time of Update: 2021-02-24
's single-day permeable patch for the treatment of Alzheimer's disease is one of the core products of Leafy Pharmaceuticals in the central nervous field.
Green leaf pharmaceutical's Liss's single-day permeable patch was developed by its German subsidiary, Luye Pharma AG, on the research and development platform for permeable drugs.
-
FDA approves Red Hill's innovative therapy, Talicia, for listing
Time of Update: 2021-02-24
today, Red Hill Biopharma announced that the U.S. FDA has approved the listing of its innovative therapy, Talicia, to treat adult patients infected with Helicobacter pyridosis.
Talicia is an FDA-approved helicobacter pyridobacteria removal therapy based on rifabutin designed to address helicobacter pyridosis resistance to antibiotics commonly used in standard care therapies.
-
Lynparza achieved its goal in a late-stage ovarian cancer trial
Time of Update: 2021-02-24
The positive results of the trial show that "standard treatment for women with advanced ovarian cancer has significant potential benefits," said Jose Baselga, executive vice president of oncology research and development.
-
The FDA has approved Bayer nubeqa ® for the treatment of patients with adenocarcinoma
Time of Update: 2021-02-24
today, Bayer announced FDA approval for Nubeqa® (darolutamide) for the treatment of patients with non-metastatic desopathic prostate cancer (nmCRPC).
Bayer has the right to commercialize the drug globally, and Orion has the option to co-promote the product in Europe.
-
Breyanzi, the CAR-T cell therapy of Shishi Shiguibo, has been approved by the FDA
Time of Update: 2021-02-24
, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb's CD19 CAR-T cell therapy, Breyanzi (lisocabtagene maraleucel, liso-cel) for the treatment of adult patients with recurring or incurable large B-cell lymphoma treated in two or more systemic treatments.
-
FDA approves new drugs for the treatment of tuberculosis, a form of lung resistance
Time of Update: 2021-02-24
That's why in our other efforts to address antimicrobial resistance, we focus on promoting the development of safe and effective new therapies that give patients more options to fight life-threatening infections.
-
Novaral's sickle cell drug gets FDA priority review
Time of Update: 2021-02-24
The regulatory agency accepted the company's Biologics Licensing Application (BLA) for the prevention of vascular ococcytosis (VOCs) in patients with sickle cell disease (SCD) and was awarded a breakthrough treatment designation in December 2018.
-
Rinvoq has been approved by the European Union to treat rheumatoid arthritis
Time of Update: 2021-02-24
Professor Andrew Cope, director of the Rheumatology Centre at King's College London, said the results of the studies meant that patients with active diseases had another treatment option with acceptable safety, which could lead to disease relief even if they did not respond adequately to drugs such as methotrexate or anti-tumor necrotizing factors.
